[Effects of differentially expressed proteins in hepatocellular carcinoma cell treated by different telomerase inhibitors].
OBJECTIVE
To detect differentially expressed proteins in hepatocellular carcinoma cell line SMMC-7721 treated separately by eight telomerase inhibitors including antisense oligodeoxynuclectide of human telomerase RNA (hTR-ASODN), sense oligodeoxynuclectide of hTR (hTR-SODN), ASODN of human telomerase reverse transcriptase (hTERT-ASODN), SODN of hTERT (hTERT-SODN), epigallocatechin gallate (EGCG), 3'-azido-3'-deoxythymidine (AZT), all trans-retinoic acid (ATRA) and adriamycin (ADM) using surface enhanced laser desorption/ionization time of flight-mass spectrom (SELDI-TOF-MS) technology.


METHODS
SELDI-TOF-MS technology and weak cation exchanger (WCX-2) protein chip were used to detect differentially expressed secretory and cytoplasmic proteins of SMMC-7721 cell treated separately by eight telomerase inhibitors. The control group was hepatocellular carcinoma SMMC-7721 cell without any disposal.


RESULTS
The results of WCX-2 protein chip showed that the secretory and cytoplasmic proteins were differentially expressed in SMMC-7721 cell treated separately by eight telomerase inhibitors. But some proteins were down-regulated or up-regulated together in all experimental groups. The molecular weight of these differential proteins were all less than 10,000 Da.


CONCLUSIONS
Differentially expressed and common changes of proteins in SMMC-7721 cell treated separately by eight telomerase inhibitors would associate with telomerase activity.
Wei
Xiao
X
Key Laboratory of Public Health and Safety,Ministry of Education, School of Public Health, Fudan University, Shanghai 200032, China. wx_smile@126.com
Zhang
Zhiyong
Z
He
Min
M
Wang
Xia
X
Zheng
Weiwei
W
D006528:Carcinoma, Hepatocellular / Q000378:metabolism; D002392:Catechin / Q000031:analogs & derivatives* / Q000494:pharmacology; D045744:Cell Line, Tumor; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006801:Humans; D008113:Liver Neoplasms / Q000378:metabolism*; D040081:Protein Array Analysis; D020543:Proteome / Q000032:analysis*; D019098:Telomerase / Q000037:antagonists & inhibitors*; D014212:Tretinoin / Q000494:pharmacology; D015215:Zidovudine / Q000494:pharmacology
D004791:Enzyme Inhibitors; D020543:Proteome; D015215:Zidovudine; D014212:Tretinoin; D002392:Catechin; C045651:epigallocatechin gallate; D019098:Telomerase